Why are tumour blood vessels abnormal and why is it important to know? - PubMed (original) (raw)

Review

Why are tumour blood vessels abnormal and why is it important to know?

J A Nagy et al. Br J Cancer. 2009.

Abstract

Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.

PubMed Disclaimer

Figures

Figure 1

Schematic diagram of the angiogenic response induced by Ad-VEGF-A164. Modified from Pettersson et al (2000).

Figure 2

Vascular patterns induced by Ad-VEGF-A164 (A, B) and by MOT, a mouse ovarian tumour (C). (A, B) FA and DV (black arrows) at 27 and 59 days after s.c. injection of 108 PFU of Ad-VEGF-A164. Most angiogenic vessels except for VMs (yellow arrows) have resolved. (C) Mouse ovarian tumour 10 days after s.c. implantation. Black arrows indicate some FA and DV; T, tumour.

Similar articles

• Can mosaic tumor vessels facilitate molecular diagnosis of cancer?
  Folkman J. Folkman J. Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):398-400. doi: 10.1073/pnas.98.2.398. Proc Natl Acad Sci U S A. 2001. PMID: 11209044 Free PMC article. No abstract available.
• Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
  Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, Dermime S, Mohammad RM, Uddin S. Siveen KS, et al. Curr Vasc Pharmacol. 2017;15(4):339-351. doi: 10.2174/1570161115666170105124038. Curr Vasc Pharmacol. 2017. PMID: 28056756 Review.
• Heterogeneity of the tumor vasculature.
  Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Nagy JA, et al. Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20. Semin Thromb Hemost. 2010. PMID: 20490982 Free PMC article. Review.
• [Targeting blood vessels for treatment of cancer...].
  Sonveaux P, Feron O. Sonveaux P, et al. J Pharm Belg. 2003;58(3):79-80. J Pharm Belg. 2003. PMID: 14619689 French. No abstract available.
• Tumour vascularization: sprouting angiogenesis and beyond.
  Hillen F, Griffioen AW. Hillen F, et al. Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502. doi: 10.1007/s10555-007-9094-7. Cancer Metastasis Rev. 2007. PMID: 17717633 Free PMC article. Review.

Cited by

• Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner.
  Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK. Chauhan VP, et al. Nat Nanotechnol. 2012 Apr 8;7(6):383-8. doi: 10.1038/nnano.2012.45. Nat Nanotechnol. 2012. PMID: 22484912 Free PMC article.
• Phloridzin Docosahexaenoate, an Omega-3 Fatty Acid Ester of a Flavonoid Precursor, Inhibits Angiogenesis by Suppressing Endothelial Cell Proliferation, Migration, and Differentiation.
  Fernando W, MacLean E, Monro S, Power Coombs MR, Marcato P, Rupasinghe HPV, Hoskin DW. Fernando W, et al. Biomolecules. 2024 Jun 27;14(7):769. doi: 10.3390/biom14070769. Biomolecules. 2024. PMID: 39062483 Free PMC article.
• Heating Induced Nanoparticle Migration and Enhanced Delivery in Tumor Treatment Using Nanotechnology.
  Gu Q, Zhu L. Gu Q, et al. Bioengineering (Basel). 2024 Sep 7;11(9):900. doi: 10.3390/bioengineering11090900. Bioengineering (Basel). 2024. PMID: 39329642 Free PMC article. Review.
• Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect.
  Huang D, Sun L, Huang L, Chen Y. Huang D, et al. J Pers Med. 2021 Feb 14;11(2):124. doi: 10.3390/jpm11020124. J Pers Med. 2021. PMID: 33672813 Free PMC article. Review.
• Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.
  Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA. Duncan R, et al. Cancer Chemother Pharmacol. 2013 Aug;72(2):417-27. doi: 10.1007/s00280-013-2209-7. Cancer Chemother Pharmacol. 2013. PMID: 23797686 Free PMC article.

References

1. 1. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287–1295 - PMC - PubMed
2. 1. Bjorndahl MA, Cao R, Burton JB, Brakenhielm E, Religa P, Galter D, Wu L, Cao Y (2005) Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res 65: 9261–9268 - PubMed
3. 1. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K (1998) Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 95: 14389–14394 - PMC - PubMed
4. 1. Carmeliet P (2003) Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet 4: 710–720 - PubMed
5. 1. Chaplin DJ, Olive PL, Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 47: 597–601 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database